Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

y of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH, and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris and the timing of regulatory and commercial milestones for Soliris in Japan. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not rei
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... 6, 2015 Moerae Matrix, a clinical ... that target inflammation and fibrosis, today announced the ... as Chief Medical Officer. Dr. ... and programs, which include a pipeline of therapies ... conditions.  Bill is an accomplished strategist and scientist ...
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... N.C. , June 21 Gentris Corporation ... pharmacogenomics, announced today that Rick Williams has ... member of the Board of Directors.  In his role ... company,s scientific leadership continues to provide biotechnology and pharmaceutical ...
... LONDON , June 21 Thomson Reuters announced ... innovative resource designed to change the way biotechnology, pharmaceutical and academic ... , , ... available free to all organizations with drugs in development. It enables ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... in southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site ... and other serious medical conditions. Screenings are affordable and accurate and run about ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... CA area, Carlson & Associates has once again teamed up with Family Emergency ... homeless families to move toward self-sufficiency. FESCO was created especially to provide emergency ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
Breaking Medicine News(10 mins):Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... suffer from musculoskeletal injuries and conditionsLAS VEGAS, Feb. 25 ... and conditions affect our quality of life every day. ... Surgeons, (AAOS) 2009 multimedia Public Service Advertising Campaign is ... scoliosis and preventing injuries in female athletes, knees. ...
... Study finds many children at risk for foot deformity due ... children are wearing shoes that are too small, according to ... of the American Academy of Orthopaedic Surgeons ( ... at high risk for developing serious foot deformities.The study, which ...
... Molecular Oncology (MOLONC) ( http://www.elsevier.com/locate/molonc ), published ... European Biochemical Societies (FEBS), has been accepted by ... Science Citation Index Expanded (SciSearch), Biosis Previews and ... times a year from January 1, 2009) highlights ...
... EAST RUTHERFORD, N.J., Feb. 25 CCA Industries, Inc. ... fiscal year ended November 30, 2008 were $57,457,946, net ... were $0.20. Revenues for the prior year were ... per share were $0.78. Revenues for the fourth ...
... University of Texas M. D. Anderson ... Gamma Knife (R) Perfexion(TM), an advanced ... or more lesions in the head in a ... http://www.newscom.com/cgi-bin/prnh/20090225/CL74742 )"Leksell Gamma Knife Perfexion suits our ...
... Feb. 20 CUREXO Technology Corporation, pioneer in ... products for orthopaedic applications, which is focused on ... has submitted a premarket notification 510(k) application to ... market clearance in the U.S. for use of ...
Cached Medicine News:Health News:The Most Breaking News in the Joint 2Health News:The Most Breaking News in the Joint 3Health News:The Most Breaking News in the Joint 4Health News:If the Shoe Fits...or Does It? 2Health News:If the Shoe Fits...or Does It? 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:CCA Industries, Inc Announces Year End Results 2Health News:CCA Industries, Inc Announces Year End Results 3Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2
... The optomap is the companys core product. ... used in primary level eye care for the ... It is available on a pay-per-patient examination basis ... with a digital wide-field of view of the ...
... Cardiac Digital Camera is a state-of-the-art, office-based nuclear ... and provides full sized fields of view. ... you need a flexible system that can work ... how the Pulse reduces the costs of adding ...
... same cryoconsole and platform technology as Freezor ... veins. Arctic Circler is an ablation tool ... that rely on medication., ,With its ... the ability to create curvilinear lesions rapidly ...
... Coil is intended for: embolization of those ... their location, or the patient's general medical ... team to be a) very high risk ... b) inoperable.,The GDC is also intended for ...
Medicine Products: